VT
AXSM icon

Vise Technologies’s Axsome Therapeutics AXSM Stock Holding History

Vise Technologies’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$605K Buy
2,473
+1,207
+95% +$262K 0.01% 1050
2026
Q1 		$231K Hold
1,266
– – ﹤0.01% 1306
2025
Q4 		$231K Buy
+1,266
New +$177K ﹤0.01% 1316

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vise Technologies's AXSM Position: Q2 2026 in Review

Vise Technologies increased its Axsome Therapeutics (AXSM) stake by 95% in Q2 2026, buying an estimated $262K and bringing the position to 2,473 shares worth $605K. The position accounts for 0.01% of the portfolio, ranked #1050.

Vise Technologies first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Vise Technologies held 2,473 shares of Axsome Therapeutics worth $605K as of Q2 2026.
  • Vise Technologies bought 1,207 Axsome Therapeutics shares in Q2 2026, an estimated $262K.
  • Axsome Therapeutics made up 0.01% of Vise Technologies's portfolio in Q2 2026, its #1050 holding.
  • Vise Technologies first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.